Trial Information

Summary: A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy

You have been asked to participate in this research study because you have advanced or metastatic (spread to other organs) cancer of the kidney(s) and your disease became worse while you were being treated with Sunitinib (Sutent). The purpose of this study is to compare the safety, side effects and effectiveness of Temsirolimus (Torisel®) and Sorafenib (Nexavar®) in treating advanced kidney cancer when given after treatment with Sunitinib (Sutent). Your participation in this study is expected to last for up to 24 months or until your disease condition gets worse, you develop unacceptable side effects, or you decide you no longer want to participate. After your treatment is complete, your medical condition will be followed indefinitely.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 3:25:58 PM